Phytic acid-based nanomedicine against mTOR represses lipogenesis and immune response for metabolic dysfunction-associated steatohepatitis therapy

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common chronic liver diseases and is mainly caused by metabolic disorders and systemic inflammatory responses. Recent studies have indicated that the activation of the mammalian (or mechanistic) target of rapamycin (mTOR) signaling participates in MASH progression by facilitating lipogenesis and regulating the immune microenvironment. Although several molecular medicines have been demonstrated to inhibit the phosphorylation or activation of mTOR, their poor specificity and side effects limit their clinical application in MASH treatment. Phytic acid (PA), as an endogenous and natural antioxidant in the liver, presents significant anti-inflammatory and lipid metabolism-inhibiting functions to alleviate MASH. In this study, considering the unique phosphate-rich structure of PA, we developed a cerium-PA (CePA) nanocomplex by combining PA with cerium ions possessing phosphodiesterase activity. CePA intervened in the S2448 phosphorylation of mTOR through the occupation effect of phosphate groups, thereby inhibiting the inflammatory response and mTOR-sterol regulatory element-binding protein 1 (SREBP1) regulation axis. The in vivo experiments suggested that CePA alleviated MASH progression and fat accumulation in high-fat diet-fed mice. Mechanistic studies validated that CePA exerts a liver-targeted mTOR repressive function, making it a promising candidate for MASH and other mTOR-related disease treatments.

Keywords

MASH / CePA / mTOR / inflammatory response / lipid metabolism

References

[1] Younossi Z , Anstee QM , Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors, and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11- 20.

[2] Powell EE , Wong VW , Rinella ME . Non-alcoholic fatty liver disease. Lancet 2021; 397: 2212- 24.

[3] Raza S , Rajak S , Upadhyay A et al. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci 2021; 26: 206- 37.

[4] Loomba R , Friedman SL , Shulman GI . Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021; 184: 2537- 64.

[5] Morrow MR , Batchuluun B , Wu J et al. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia. Cell Metab 2022; 34: 919- 36.e8.

[6] Oriquat G , Masoud IM , Kamel MA et al. The anti-obesity and anti-steatotic effects of chrysin in a rat model of obesity mediated through modulating the hepatic AMPK/mTOR/lipogenesis pathways. Molecules 2023; 28: 1734.

[7] Feng J , Qiu S , Zhou S et al. mTOR: a potential new target in non-alcoholic fatty liver disease. Int J Mol Sci 2022; 23: 9196.

[8] Zhang S , Mao Y , Fan X . Inhibition of ghrelin O-acyltransferase attenuated lipotoxicity by inducing autophagy via AMPK-mTOR pathway. Drug Design Develop Ther 2018; 12: 873- 85.

[9] Kotlyarov S , Bulgakov A . Lipid metabolism disorders in the comorbid course of nonalcoholic fatty liver disease and chronic obstructive pulmonary disease. Cells 2021; 10: 2978.

[10] Ma X , Qian H , Chen A et al. Perspectives on mitochondria-ER and mitochondria-lipid droplet contact in hepatocytes and hepatic lipid metabolism. Cells 2021; 10: 2273.

[11] Zhou Z , Fan T , Yan Y et al. One stone with two birds: phytic acidcapped platinum nanoparticles for targeted combination therapy of bone tumors. Biomaterials 2019; 194: 130- 8.

[12] Da Silva EO , Gerez JR , Hohmann MSN et al. Phytic acid decreases oxidative stress and intestinal lesions induced by fumonisin B1 and deoxynivalenol in intestinal explants of pigs.Toxins 2019; 11: 18.

[13] Foster SR , Dilworth LL , Omoruyi FO et al. Pancreatic and renal function in streptozotocin-induced type 2 diabetic rats administered combined inositol hexakisphosphate and inositol supplement. Biomed Pharmacother 2017; 96: 72- 7.

[14] Badodi S , Pomella N , Zhang X et al. Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation. Nat Commun 2021; 12: 2148.

[15] Ran X , Hu G , Li F et al. Phytic acid improves hepatic steatosis, inflammation, and oxidative stress in high-fat diet (HFD)-fed mice by modulating the gut-liver axis. J Agric Food Chem 2022; 70: 11401- 11.

[16] Singh A , Singh SP , Bamezai R . Modulatory influence of arecoline on the phytic acid-altered hepatic biotransformation system enzymes, sulfhydryl content and lipid peroxidation in a murine system. Cancer Lett 1997; 117: 1- 6.

[17] Sandström J , Balian A , Lockowandt R et al. IP6K2 predicts favorable clinical outcome of primary breast cancer. Mol Clin Oncol 2021; 14: 94.

[18] Kim YG , Lee Y , Soh M et al. Ceria-based therapeutic antioxidants for biomedical applications. Adv Mater 2024; 36: e2210819.

[19] Wu J , Wang X , Wang Q et al. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II). Chem Soc Rev 2019; 48: 1004- 76.

[20] Zhou F , Li M , Chen M et al. Redox homeostasis strategy for inflammatory macrophage reprogramming in rheumatoid arthritis based on ceria oxide nanozyme-complexed biopolymeric micelles. ACS Nano 2023; 17: 4358- 72.

[21] Wang L , Qiu S , Li X et al. Myocardial-targeting tannic cerium nanocatalyst attenuates ischemia/reperfusion injury. Angew Chem Int Ed Engl 2023; 62: e202305576.

[22] Fu X , Yu X , Jiang J et al. Small molecule-assisted assembly of multifunctional ceria nanozymes for synergistic treatment of atherosclerosis. Nat Commun 2022; 13: 6528.

[23] Singh N , Sherin GR , Mugesh G . Antioxidant and prooxidant nanozymes: from cellular redox regulation to next-generation therapeutics. Angew Chem Int Ed Engl 2023; 62: e202301232.

[24] Gao Y , Liu S , Zeng X et al. Reduction of reactive oxygen species accumulation using gadolinium-doped ceria for the alleviation of atherosclerosis. ACS Appl Mater Interfaces 2023; 15: 10414- 25.

[25] Weng Q , Sun H , Fang C et al. Catalytic activity tunable ceria nanoparticles prevent chemotherapy-induced acute kidney injury without interference with chemotherapeutics. Nat Commun 2021; 12: 1436.

[26] Song Y , You Q , Chen X . Transition metal-based therapies for inflammatory diseases. Adv Mater 2023; 35: e2212102.

[27] Ma Y , Tian Z , Zhai W et al. Insights on catalytic mechanism of CeO₂ as multiple nanozymes. Nano Res 2022; 15: 10328- 42.

[28] Tu Z , Zhong Y , Hu H et al. Design of therapeutic biomaterials to control inflammation. Nat Rev Mater 2022; 7: 557- 74.

[29] Wen Y , Chen L , Zhou L et al. Bionic receptor for atherosclerosis therapy: molecularly imprinted polymers mediate unique cholesterol efflux and inhibit inflammation. Chem Eng J 2022; 430: 132870.

[30] Yang J , Bai Y , Shen S et al. An oral nano-antioxidant for targeted treatment of inflammatory bowel disease by regulating macrophage polarization and inhibiting ferroptosis of intestinal cells. Chem Eng J 2023; 465: 142940.

[31] Scheuchzer P , Syryamina VN , Zimmermann MB et al. Ferric pyrophosphate forms soluble iron coordination complexes with zinc compounds and solubilizing agents in extruded rice and predicts increased iron solubility and bioavailability in young women. J Nutr 2023; 153: 636- 44.

[32] Ashley IA , Kitchen SA , Gorman LM et al. Genomic conservation and putative downstream functionality of the phosphatidylinositol signaling pathway in the cnidarian-dinoflagellate symbiosis. Front Microbiol 2022; 13: 1094255.

[33] Wang Z , Li S , Wang R et al. The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD). Mol Med 2020; 26: 54.

[34] Tsuji A , Yoshikawa S , Ikeda Y et al. Tactics with prebiotics for the treatment of metabolic dysfunction-associated fatty liver disease via the improvement of mitophagy. Int J Mol Sci 2023; 24: 5465.

[35] Chen N , Mu L , Yang Z et al. Carbohydrate response elementbinding protein regulates lipid metabolism via mTOR complex 1 in diabetic nephropathy. J Cell Physiol 2021; 236: 625- 40.

[36] Munir MT , Halim SA , Santos JM et al. A high dose of calcitriol inhibits glycolysis and M2 macrophage polarization in the tumor microenvironment by repressing mTOR activation: in vitro and molecular docking studies. Cell Physiol Biochem 2023; 57: 105- 22.

[37] Cai J , Peng J , Feng J et al. Antioxidant hepatic lipid metabolism can be promoted by orally administered inorganic nanoparticles. Nat Commun 2023; 14: 3643.

[38] Liang M , Tan H , Zhou J et al. Bioengineered hferritin nanocages for quantitative imaging of vulnerable plaques in atherosclerosis. ACS Nano 2018; 12: 9300- 8.

[39] Cheng J , Zhang Y , Ge Y et al. Sodium butyrate promotes milk fat synthesis in bovine mammary epithelial cells via GPR41 and its downstream signaling pathways. Life Sci 2020; 259: 118375.

[40] Yang Q , Guan KL . Expanding mTOR signaling. Cell Res 2007; 17: 666- 81.

[41] Gheryani S , Coffelt SB , Gartland A et al. Generation of a novel mouse model for the inducible depletion of macrophages in vivo. Genesis 2013; 51: 41- 9.

[42] Ji X , Du W , Che W et al. Apigenin inhibits the progression of osteoarthritis by mediating macrophage polarization. Molecules 2023; 28: 2915.

[43] Tian T , Wang Z , Chen L et al. Photobiomodulation activates undifferentiated macrophages and promotes M1/M2 macrophage polarization via PI3K/AKT/mTOR signaling pathway. Lasers Med Sci 2023; 38: 86.

[44] Hao Y , Song K , Tan X et al. Reactive oxygen species-responsive polypeptide drug delivery system targeted activated hepatic stellate cells to ameliorate liver fibrosis. ACS Nano 2022; 16: 20739- 57.

[45] Li DK , Chaudhari SN , Lee Y et al. Inhibition of microbial deconjugation of micellar bile acids protects against intestinal permeability and liver injury. Sci Adv 2022; 8: eabo2794.

[46] Zhao M , Jin Z , Xia C et al. Inhibition of free heme-catalyzed Fenton-like reaction prevents non-alcoholic fatty liver disease by hepatocyte-targeted hydrogen delivery. Biomaterials 2023; 301: 122230.

[47] Bai B , Qi S , Yang K et al. Self-assembly of selenium-doped carbon quantum dots as antioxidants for hepatic ischemia-reperfusion injury management. Small 2023; 19: e2300217.

[48] Chalasani N , Younossi Z , Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328- 57.

[49] Angulo P , Machado MV , Diehl AM . Fibrosis in nonalcoholic fatty liver disease: mechanisms and clinical implications. Semin Liver Dis 2015; 35: 132- 45.

[50] Ekstedt M , Hagström H , Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547- 54.

[51] Younossi ZM , Koenig AB , Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73- 84.

[52] Michelotti A , de Scordilli M , Palmero L et al. NAFLD-related hepatocellular carcinoma: the malignant side of metabolic syndrome. Cells 2021; 10: 2034.

[53] Xu L , Liu W , Bai F et al. Hepatic macrophage as a key player in fatty liver disease. Front Immunol 2021; 12: 708978.

[54] Roohani S , Tacke F . Liver injury and the macrophage issue: molecular and mechanistic facts and their clinical relevance. Int J Mol Sci 2021; 22: 7249.

[55] Tao H , Guo J , Ma Y et al. Luminescence imaging of acute liver injury by biodegradable and biocompatible nanoprobes. ACS Nano 2020; 14: 11083- 99.

[56] Yang G , Ni JS , Li Y et al. Acceptor engineering for optimized ROS generation facilitates reprogramming macrophages to M1 phenotype in photodynamic immunotherapy. Angew Chem Int Ed Engl 2021; 60: 5386- 93.

[57] Yu S , Wang J , Zheng H et al. Pathogenesis from inflammation to cancer in NASH-derived HCC. J Hepatocellular Carcinoma 2022; 9: 855- 67.

[58] Guo JW , Liu X , Zhang TT et al. Hepatocyte TMEM16A deletion retards NAFLD progression by ameliorating hepatic glucose metabolic disorder. Adv Sci 2020; 7: 1903657.

[59] Liu X , Duan N , Liu C et al. Characterization of a murine nonalcoholic steatohepatitis model induced by high fat high calorie diet plus fructose and glucose in drinking water. Lab Invest 2018; 98: 1184- 99.

RIGHTS & PERMISSIONS

The Author(s). Published by Oxford University Press on behalf of Higher Education Press.